Prostate and other male cancers:

Indications for: CAMCEVI

Advanced prostate cancer.

Adult Dosage:

Give by SC inj on the upper- or mid-abdominal area. Avoid areas with brawny or fibrous tissue or locations that could be rubbed or compressed. 42mg once every 6months.

Children Dosage:

Not established.

CAMCEVI Contraindications:

Hypersensitivity to GnRH analogues.

CAMCEVI Warnings/Precautions:

May worsen metastatic vertebral lesions and/or urinary tract obstruction; monitor closely during first few weeks. Increased risk of diabetes, MI, sudden cardiac death, stroke. Monitor blood glucose, HbA1c, and for CVD signs/symptoms during therapy. Risk of QT prolongation in those with congenital long QT syndrome, CHF, or frequent electrolyte abnormalities. Correct and monitor electrolyte abnormalities; consider monitoring ECGs. Monitor serum testosterone levels post-inj. Embryo-fetal toxicity. Pregnancy. Nursing mothers: not recommended.

CAMCEVI Classification:

GnRH analogue.

CAMCEVI Interactions:

Caution with concomitant drugs known to prolong the QT interval.

Adverse Reactions:

Hot flush, hypertension, inj site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, pain in extremity; spinal cord compression, hyperglycemia, convulsions.

Generic Drug Availability:


How Supplied:

Kit—1 (w. supplies)